Northwest Veterinary Specialists, Runcorn, UK.
Wear Referrals, Bradbury, UK.
J Feline Med Surg. 2022 Aug;24(8):e183-e193. doi: 10.1177/1098612X221098961. Epub 2022 May 31.
Biological behaviour and treatment options of non-injection-site soft tissue sarcomas (nFISS) in cats are less well understood than in dogs. The aim of this retrospective study was to assess the outcomes of cats with nFISS following treatment with adjuvant radiotherapy.
The medical records of cats with soft tissue sarcomas in locations not associated with, and histology reports not suggestive of, injection-site sarcomas were reviewed. All cats underwent adjuvant radiotherapy, either hypofractionated (32-36 Gy delivered in weekly 8-9 Gy fractions) or conventionally fractionated (48-54 Gy delivered in 16-18 3 Gy fractions) to microscopic disease.
In total, 18 cats were included in the study, 17 with extremity nFISS and one with facial nFISS. Nine received radiotherapy after a single surgery and nine after multiple surgeries for recurrent nFISS. Eight cats were treated with a hypofractionated protocol and 10 with a conventionally fractionated protocol. The median follow-up time was 540 days (range 51-3317 days). The tumour recurred in eight (44.4%) cats following adjuvant radiotherapy; it recurred in three (37.5%) cats following a hypofractionated protocol and in five (50%) cats following a conventionally fractionated protocol. The overall median progression-free interval (PFI) for 17/18 cats was 2748 days, while the median PFI for the 7/8 cats with recurrence was 164 days. The recurrence for one cat was reported, but the date was unknown and it was therefore censored from these data. When stratifying based on the protocol, the median PFI for hypofractionated and conventionally fractionated protocols was 164 days and 2748 days, respectively. Statistically, there was no significant difference between the two protocols ( = 0.636).
Adjuvant radiotherapy resulted in good long-term tumour control in 12/18 cats with nFISS. Further studies in larger populations are required to assess the significance of radiation dose and fractionation on tumour control and the effect of multiple surgeries prior to initiation of radiotherapy on outcome.
与注射部位无关的非注射部位软组织肉瘤(nFISS)的生物学行为和治疗选择在猫中比在狗中了解得更少。本回顾性研究的目的是评估接受辅助放疗的 nFISS 猫的治疗结果。
回顾性分析了组织学报告不提示注射部位肉瘤的非注射部位软组织肉瘤猫的病历。所有猫均接受辅助放疗,低分割(32-36Gy 每周 8-9Gy 分次)或常规分割(48-54Gy 16-18 次 3Gy 分次)治疗显微镜下疾病。
共纳入 18 只猫,17 只为四肢 nFISS,1 只为面部 nFISS。9 只猫在单次手术后接受放疗,9 只猫在多次手术切除复发 nFISS 后接受放疗。8 只猫接受低分割方案治疗,10 只猫接受常规分割方案治疗。中位随访时间为 540 天(范围 51-3317 天)。辅助放疗后,8 只(44.4%)猫肿瘤复发;3 只(37.5%)接受低分割方案治疗,5 只(50%)接受常规分割方案治疗。17/18 只猫的总体中位无进展生存期(PFI)为 2748 天,7/8 只复发猫的中位 PFI 为 164 天。一只猫的复发情况有报道,但日期不详,因此这些数据中被删失。基于方案分层时,低分割和常规分割方案的中位 PFI 分别为 164 天和 2748 天。统计学上,两种方案之间无显著差异( = 0.636)。
辅助放疗可使 12/18 只 nFISS 猫获得良好的长期肿瘤控制。需要在更大的人群中进行进一步的研究,以评估辐射剂量和分割对肿瘤控制的意义,以及在开始放疗前多次手术对结果的影响。